Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL)

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why I maintain a Hold rating on VIGL.